Resultados de la búsqueda 351-360 of 1969 for GLP-1 secretion
Address 1. Infórmate más sobre cómo usa Mayo Clinic los datos. Usamos los datos que pusiste para ofrecerte el contenido solicitado. Para proporcionarte la ...
The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly variable and typically characterized by progressive enlargement of ...
Page 1. Page 2. Page 3. Page 4. Page 5. Page 6. Page 7. Page 8.
After enrollment, patients will receive one cycle of Induction chemotherapy. ... Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be ...
The purpose of this study is to determine the rate at which patients who underwent Spinal Cord Stimulation (SCS) trial ultimately progressed to SCS ...
... (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...
The overall objective of this study is to define genes causing cystic kidney disease and to determine the degree to which variants at these cystic kidney ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?